Make a Gift
Read Our Blog
From Medical News Today
A new method that allows antibodies to penetrate cyst walls may open the door for already approved drugs to target the growth factors that drive polycystic kidney disease.
TUCSON, Ariz., June 1, 2015 – The Critical Path Institute (C-Path) announced today that the U.S. Food and Drug Administration (FDA) has issued a Letter of Support to C-Path's Polycystic Kidney Disease Outcomes Consortium (PKDOC) for the use of total kidney volume (TKV) as a prognostic biomarker to select patients for clinical trials of new therapies for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
New Orleans Saintsations Kriste Lewis, along with others impacted by PKD, helps create awareness in this promotional video. Please help spread the word to people who may not know about this disease by sharing this video.
2000 Daniel Island Drive, Charleston SC 29492
Phone: 800.443.9441 | Fax: email@example.com
©2015, PKD Foundation ·The PKD Foundation is a 501 (c)(3), 509 (a)(1) public charity.